BIOTECH GROWTH N V - 01 Nov 2024 Form 4 Insider Report for ESSA Pharma Inc. (EPIX)

Reporting relationship: 10%+ Owner
Issuer ticker: EPIX
Reported as of: 01 Nov 2024
Net transaction value: -$12,018,409
SEC form: 4
Accepted by SEC: 05 Nov 2024, 12:06:18 UTC
Prior SEC filing: 19 Oct 2023
Next SEC filing: 20 Mar 2025
Source filing: View source filing
Reporting owner signature: By: /s/Martin Gubler

Key filing fact

BIOTECH GROWTH N V filed Form 4 for ESSA Pharma Inc. (EPIX) on 05 Nov 2024.

Key facts

This page summarizes BIOTECH GROWTH N V's Form 4 filing for ESSA Pharma Inc. (EPIX).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 05 Nov 2024, 12:06.

Change

Previous filing in this sequence was filed on 19 Oct 2023.
Current net transaction value: -$12,018,409.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EPIX transaction

Common Shares

Sale

Transaction value: $3,064,000
Shares: -2,000,000
Change %: -25%
Price: $1.53
Shares after: 5,879,583
Date: 01 Nov 2024
Ownership: Direct

EPIX transaction

Common Shares

Sale

Transaction value: $3,051,800
Shares: -2,000,000
Change %: -34%
Price: $1.53
Shares after: 3,879,583
Date: 01 Nov 2024
Ownership: Direct

EPIX transaction

Common Shares

Sale

Transaction value: $3,058,800
Shares: -2,000,000
Change %: -52%
Price: $1.53
Shares after: 1,879,583
Date: 01 Nov 2024
Ownership: Direct

EPIX transaction

Common Shares

Sale

Transaction value: $2,843,809
Shares: -1,879,583
Change %: -100%
Price: $1.51
Shares after: 0
Date: 01 Nov 2024
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

BIOTECH GROWTH N V is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

SEC remarks

Biotech Growth N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of ESSA Pharma Inc. held directly or indirectly by Biotech Growth N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Growth N.V.